<DOC>
	<DOCNO>NCT00734448</DOCNO>
	<brief_summary>Myo-Inositol insulin sensitize agent ameliorate insulin resistance woman affect gestational diabetes ( GDM ) , information effect glucose profile . Maternal hyperglycemia GDM , especially hypoglycemic excursion , associate adverse pregnancy outcome . Continuous Glucose Monitoring System ( CGMS ) obviously well intermittent self monitor detect glucose profile magnitude duration glucose fluctuation . For reason , propose clinical trial analyze characteristic glucose variability GDM woman , treat diet folic acid alone diet , folic acid myo-inositol supplementation .</brief_summary>
	<brief_title>Myo-inositol Administration Gestational Diabetes</brief_title>
	<detailed_description>Our study randomize , prospective , controlled trial , include first 30 consecutive Caucasian gestational diabetes patient diagnose , accord International Association Diabetes Pregnancy Study Group ( IADPSG ) panel criterion , November 2013 Department Obstetric Gynecology Messina University ( ITALY ) . After informed consent randomly assign receive ( n. 15 ) diet folic acid ( 400 mcg per day ) alone ( n. 15 ) diet , folic acid ( 400 mcg per day ) myo-inositol ( 2 g. twice day ) supplementation . The insulin sensitivity index ( HOMA-IR ) glycemic profile monitor CGMS patient GDM diagnosis 8 week treatment The pregnant woman delivery time treatment ( 8 week ) need insulin exclude .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes , Gestational</mesh_term>
	<mesh_term>Inositol</mesh_term>
	<criteria>Gestational diabetes diagnose within 28 week Caucasian pregnant woman Non Caucasian pregnant woman Delivery 8 week treatment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>gestational diabetes mellitus</keyword>
	<keyword>carbohydrate intolerance</keyword>
	<keyword>myo-inositol</keyword>
	<keyword>insulin resistance</keyword>
</DOC>